Search -

Displaying 21 - 40 of 47

Sort: Relevancy | Date

New ESC Prevention Guidelines Focus on Tailored, Escalating Therapy

News Conference News ESC 2021

New ESC Prevention Guidelines Focus on Tailored, Escalating Therapy

Michael O'Riordan

September 03, 2021

March 2021 News Roundup

News Opinion CV Team Dispatch

March 2021 News Roundup

March 01, 2021

New Advanced Training Outlined for Future Vascular Medicine Specialists

News Daily News

New Advanced Training Outlined for Future Vascular Medicine Specialists

Michael O'Riordan

January 21, 2021

AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More

News Daily News

AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More

December 17, 2020

VOYAGER PAD: CAD Subanalysis Finds Fewer CV, Limb Events With Rivaroxaban

News Conference News ESC 2020

VOYAGER PAD: CAD Subanalysis Finds Fewer CV, Limb Events With Rivaroxaban

September 03, 2020

Ideal CV Health Over the Long Term Linked With Better Survival, Less Disease

News Daily News

Ideal CV Health Over the Long Term Linked With Better Survival, Less Disease

Michael O'Riordan

March 13, 2020

SKIP Questions Need for IV Thrombolysis Before Stroke Thrombectomy

News Conference News ISC 2020

SKIP Questions Need for IV Thrombolysis Before Stroke Thrombectomy

February 25, 2020

Statins Started in Kids With FH Provide Benefits in Adulthood

News Daily News

Statins Started in Kids With FH Provide Benefits in Adulthood

Yael L. Maxwell

October 17, 2019

Which ASCVD Patients Will Benefit Most From Rivaroxaban Plus Aspirin? Some Clues

News Daily News

Which ASCVD Patients Will Benefit Most From Rivaroxaban Plus Aspirin? Some Clues

June 26, 2019

Now You See It: Imaging Helps Lower CVD Risk Burden in Primary Prevention

News Daily News

Now You See It: Imaging Helps Lower CVD Risk Burden in Primary Prevention

Michael O'Riordan

December 10, 2018

Consulting the COMPASS for Rivaroxaban’s Role in Peripheral Vascular Disease

News Conference News VIVA 2018

Consulting the COMPASS for Rivaroxaban’s Role in Peripheral Vascular Disease

November 15, 2018

Intracranial Hemorrhage Outside of A-fib: Different NOACs, Different Risks

News Daily News

Intracranial Hemorrhage Outside of A-fib: Different NOACs, Different Risks

August 13, 2018

COMPASS Analysis Explores Impact of Low-Dose Rivaroxaban Plus Aspirin on Stroke

News Conference News ISC 2018

COMPASS Analysis Explores Impact of Low-Dose Rivaroxaban Plus Aspirin on Stroke

January 25, 2018

Subclinical Atherosclerosis Evident in Half of Adults Without CVD Risk Factors

News Daily News

Subclinical Atherosclerosis Evident in Half of Adults Without CVD Risk Factors

Michael O'Riordan

December 12, 2017

Low-Dose Rivaroxaban Plus Aspirin Lowers Some Costs in COMPASS, but Full Economic Impact Unclear

News Conference News AHA 2017

Low-Dose Rivaroxaban Plus Aspirin Lowers Some Costs in COMPASS, but Full Economic Impact Unclear

November 14, 2017

TCTMD’s Top 10 Most Popular Stories for October 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2017

October 29, 2017

What is the Right Antiplatelet Therapy for Symptomatic Carotid Disease?

Presentation VIVA 2017

What is the Right Antiplatelet Therapy for Symptomatic Carotid Disease?

Presenter: William Gray

September 21, 2017

COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease

News Conference News ESC 2017

COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease

August 27, 2017

Many Stroke Patients Stop Statins or Never Start, With Dire Consequences

News Daily News

Many Stroke Patients Stop Statins or Never Start, With Dire Consequences

Michael O'Riordan

August 02, 2017

3-D Ultrasound Quantifies Plaque Burden in Healthy Middle-Aged Cohort

News Daily News

3-D Ultrasound Quantifies Plaque Burden in Healthy Middle-Aged Cohort

Michael O'Riordan

July 11, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.